Oncolab S.R.L.

The trials here

What the 27 trials at this site are about, from their registry records.

Conditions

• Lung cancer22 trials
• Melanoma2 trials
• Metastatic breast cancer2 trials
• Head and neck cancer1 trial
• Ovarian cancer1 trial
• Prostate cancer1 trial

Phase

• Phase 322 trials
• Phase 23 trials
• Phase 2/32 trials

Status

• Completed11 trials
• Active, not recruiting9 trials
• Recruiting6 trials
• Not yet recruiting1 trial

Lead sponsor

• AstraZeneca3 trials
• H e x a l AG2 trials
• Maia Biotechnology2 trials
• Mirati Therapeutics Inc.2 trials
• AbbVie1 trial
• and 17 more

Running trials

• Not yet recruiting

  A Study to Investigate the Efficacy and Safety of Letrozole SIE Compared With Femara® (Both Combined With the CDK4/6 Inhibitor Ribociclib) in Postmenopausal Women With HR-Positive, HER2-Negative, Inoperable Locally Advanced or Metastatic Breast Cancer

  NCT07340658· Phase 3· Rovi Pharmaceuticals Laboratories· Source

• Recruiting

  A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC

  NCT06908304· Phase 3· Maia Biotechnology· Source

• Recruiting

  Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

  NCT06982521· Phase 3· Relay Therapeutics, Inc.· Source

• Recruiting

  This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

  NCT06758401· Phase 3· Pfizer· Source

• Recruiting

  A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

  NCT06868277· Phase 3· AstraZeneca· Source

• Active, not recruiting

  Phase 2/3 Randomized Study of INBRX-106 Add-on to Pembrolizumab in First-Line PD-L1 CPS ≥20 R/M HNSCC (HexAgon-HN)

  2024-515538-34-00· Phase 2/3· Inhibrx Biosciences Inc.· Source

• Active, not recruiting

  A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)

  NCT06687369· Phase 3· mAbxience Research S.L.· Source

• Active, not recruiting

  A study to continue providing GME751 (a new medicine that is similar to pembrolizumab) to participants who are eligible for pembrolizumab treatment after participation in previous studies (CGME751A12101 or CGME751A12301)

  2024-513160-25-00· Phase 3· H e x a l AG· Source

• Recruiting

  A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

  NCT06452277· Phase 3· Bayer· Source

• Active, not recruiting

  Study which tests 2 medications (SB27, Keytruda) to compare how effective, safe and well tolerated in a large number of metastatic non-squamous non-small cell lung cancer patients

  2023-507448-36-00· Phase 3· Samsung Bioepis Co. Ltd.· Source

• Active, not recruiting

  A Study to Evaluate ABP 206 Compared with OPDIVO® (Nivolumab) in Subjects with Unresectable or Metastatic Melanoma

  2023-503288-40-00· Phase 3· Amgen Inc.· Source

• Active, not recruiting

  THIO Sequenced With Cemiplimab in Advanced NSCLC

  NCT05208944· Phase 2· Maia Biotechnology· Source

• Recruiting

  A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

  NCT04928846· Phase 3· AbbVie· Source

• Active, not recruiting

  Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy

  NCT04655976· Phase 2/3· GlaxoSmithKline· Source

• Active, not recruiting

  Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer

  NCT03937154· Phase 3· Amgen· Source

• Active, not recruiting

  A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC

  NCT02489318· Phase 3· Aragon Pharmaceuticals, Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer5 recruiting
• Metastatic breast cancer2 recruiting

Closed trials

• Active, not recruiting

  Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)

  NCT06726265· Phase 3· Immutep S.A.S.· Source

• Recruiting

  A Randomized, Double-Blind, Placebo-Controlled, MultiRegional Phase III Clinical Study of Toripalimab Alone or in Combination With Tifcemalimab (JS004/TAB004) as Consolidation Therapy in Patients With Limited-Stage Small Cell Lung Cancer Without Disease Progression Following Chemoradiotherapy

  2023-507097-41-01· Phase 3· Shanghai Junshi Biosciences Co. Ltd.· Source

• Completed

  A study to compare effects and safety of CT-P51 and Keytruda in patients with previously untreated metastatic lung cancer

  2024-514048-98-00· Phase 3· Celltrion Inc.· Source

• Completed

  A study to compare efficacy, safety, and immune response of GME751 and EU-authorized Keytruda in adult participants with untreated metastatic lung cancer

  2023-506882-70-00· Phase 3· H e x a l AG· Source

• Active, not recruiting

  Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)

  NCT05853575· Phase 2· Mirati Therapeutics Inc.· Source

• Active, not recruiting

  A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy

  NCT05450692· Phase 3· AstraZeneca· Source

• Completed

  Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)

  NCT05153239· Phase 3· PharmaMar· Source

• Active, not recruiting

  A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection

  NCT05120349· Phase 3· AstraZeneca· Source

• Active, not recruiting

  Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

  NCT04685135· Phase 3· Mirati Therapeutics Inc.· Source

• Completed

  A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

  NCT04623775· Phase 2· Bristol-Myers Squibb· Source

• Completed

  Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC

  NCT02273375· Phase 3· Canadian Cancer Trials Group· Source